熱門資訊> 正文
Chimerix GAAP每股收益为-0.25美元，低于0.01美元，收入为0.06万美元，差0.25万美元
2025-03-21 18:07
- Chimerix press release (NASDAQ:CMRX): Q4 GAAP EPS of -$0.25 beats by $0.01.
- Revenue of $57K (vs. $4K Y/Y) misses by $0.25M.
- Chimerix’s balance sheet at December 31, 2024 included $140.1 million of capital available to fund operations, no outstanding debt, and approximately 92.2 million outstanding shares of common stock.
- Chimerix’s balance sheet at December 31, 2024 included $140.1 million of capital available to fund operations, no outstanding debt, and approximately 92.2 million outstanding shares of common stock.
More on Chimerix
- Jazz Buys Chimerix - A Good Deal To Make With Major Approval Catalyst In Play
- Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients
- Chimerix gains on FDA priority review for brain tumor drug
- Biggest stock movers Tuesday: INTC, DAL, STZ, HEES, and more
- Seeking Alpha’s Quant Rating on Chimerix
推薦文章
華盛早報丨要求審查美聯儲！美財長貝森特激進發言；"Meme股"黑馬Opendoor再暴漲42%觸發熔斷
特朗普媒體公司囤積20億美元比特幣！加密貨幣推動特朗普淨資產大幅增長
聚焦中概 | 蔚來漲近6%，文遠知行漲逾5%
美股異動 | OPEN暴漲超41%！納微半導體大漲超25%
美股機會日報丨以太幣儲備概念股盤前大漲！穩定幣監管法案正式簽署；高盛預計美股未來12個月再漲10%
AI和機器人有望刺激特斯拉股價？財報季提前部署期權策略
華盛早報丨科技「七巨頭「財報來襲定調美股走向！金融科技公司Block獲入標普500指數
港股周報丨三家外賣平臺被約談！「瘋狂星期六」或不再瘋狂；花旗呼籲增持中國互聯網、科技及消費板塊
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
